Market Research Logo

Global Anti-obesity Drugs Market 2018-2022

Global Anti-obesity Drugs Market 2018-2022

About this market

The research on drugs that target obesity and type 2 diabetes mellitus to gain traction in the market. The global epidemic obesity and type 2 diabetes is increasing. This demands for increasing focus on the drugs that can control obesity and diabetes. Technavio’s analysts have predicted that the anti-obesity drugs market will register a CAGR of almost 8% by 2023.

Market Overview

Global increase in both incidence and prevalence of obesity

The prevalence and incidence rate of obesity is very high because of the limited efficacy of currently available drugs. The prevalence of obesity remains the highest in the US over the past two decades. Thus, the shoot in the rates of obesity across the world offers huge opportunities for drug manufacturing vendors to manufacture innovative and highly effective drugs.

Limited reimbursement for anti-obesity drugs

Although US is the major market for anti-obesity drugs, the challenges associated with the reimbursement of these drugs is more in the US. The bariatric surgery can recover weight related issues and is life-saving, but the concern for financial burden remains. People are unwilling to pay for this surgery as they believe that obesity is a cosmetic or lifestyle issue, which led player limit coverage.

For the detailed list of factors that will drive and challenge the growth of the anti-obesity drugs market during the 2018-2022, view our report.

Competitive Landscape

The market appears to be concentrated and with the presence of few companies including Eisai and Novo Nordisk the competitive environment is quite intense. Factors such as the increase in childhood obesity incidence and the use of implantable neuroregulatory devices for treating obesity, will provide considerable growth opportunities to anti-obesity drugs manufactures. Eisai, Novo Nordisk, and Vivus are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market to witness the presence of a few international and regional anti-obesity drug companies who offer obesity treatment drugs for mechanism such as centrally-acting and peripherally-acting anti-obesity drugs.’


PRESS RELEASE

Technavio Announces the Publication of its Research Report – Global Anti-obesity Drugs Market 2018-2022

Technavio recognizes the following companies as the key players in the global anti-obesity drugs market: Eisai, Novo Nordisk, and Vivus.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the research on drugs that target obesity and type 2 diabetes mellitus.”

According to the report, one of the major drivers for this market is the Global increase in both incidence and prevalence of obesity.

Further, the report states that one of the major factors hindering the growth of this market is the Limited reimbursement for anti-obesity drugs.

Companies Mentioned

Eisai

Novo Nordisk

Vivus

  • Executive summary
  • Scope of the report
  • Research methodology
  • Market landscape
    • Market ecosystem
      • Table Parent market
      • Table Global metabolic disorder therapeutics market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2017
      • Table Market size 2017
      • Table Validation techniques employed for market sizing 2017
    • Market size and forecast 2017-2022
      • Table Global - Market size and forecast 2017-2022 ($ mn)
      • Table Global - Year-over-year growth 2018-2022 (%)
  • Five forces analysis
    • Table Five forces analysis 2017
    • Table Five forces analysis 2022
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2017
  • Pipeline analysis
  • Market segmentation by drugs based on class of obesity
    • Segmentation by drugs based on class of obesity
      • Table Drugs based on class of obesity - Market share 2017-2022 (%)
    • Comparison by drugs based on class of obesity
      • Table Comparison by drugs based on class of obesity
    • Class I anti-obesity drugs - Market size and forecast 2017-2022
      • Table Class I anti-obesity drugs - Market size and forecast 2017-2022 ($ mn)
      • Table Class I anti-obesity drugs - Year-over-year growth 2018-2022 (%)
    • Class II anti-obesity drugs - Market size and forecast 2017-2022
      • Table Class II anti-obesity drugs - Market size and forecast 2017-2022 ($ mn)
      • Table Class II anti-obesity drugs - Year-over-year growth 2018-2022 (%)
    • Class III anti-obesity drugs - Market size and forecast 2017-2022
      • Table Class III anti-obesity drugs - Market size and forecast 2017-2022 ($ mn)
      • Table Class III anti-obesity drugs - Year-over-year growth 2018-2022 (%)
    • Market opportunity by drugs based on class of obesity
      • Table Market opportunity by drugs based on class of obesity
  • Market segmentation by mechanism of action
    • Segmentation by mechanism of action
  • Customer landscape
    • Table Customer landscape
  • Regional landscape
    • Geographical segmentation
      • Table Global - Market share by geography 2017-2022 (%)
    • Regional comparison
      • Table Regional comparison
    • Americas - Market size and forecast 2017-2022
      • Table Americas - Market size and forecast 2017-2022 ($ mn)
      • Table Americas - Year-over-year growth 2018-2022 (%)
      • Table Top three countries in Americas
    • EMEA - Market size and forecast 2017-2022
      • Table EMEA - Market size and forecast 2017-2022 ($ mn)
      • Table EMEA - Year-over-year growth 2018-2022 (%)
      • Table Top three countries in EMEA
    • APAC - Market size and forecast 2017-2022
      • Table APAC - Market size and forecast 2017-2022 ($ mn)
      • Table APAC - Year-over-year growth 2018-2022 (%)
      • Table Top three countries in APAC
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
  • Market trends
    • Research on drugs that target both obesity and type 2 diabetes mellitus
      • Table List of target drugs for obesity and type 2 diabetes mellitus
    • Increase in childhood obesity incidence
    • Use of implantable neuroregulatory devices for treating obesity
    • Increase in morbid obesity incidence
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • Eisai
      • Table Eisai - Overview
      • Table Eisai - Business segments
      • Table Eisai - Organizational developments
      • Table - Geographic focus
      • Table Eisai - Key offerings
    • Novo Nordisk
      • Table Novo Nordisk - Overview
      • Table Novo Nordisk - Business segments
      • Table Novo Nordisk - Organizational developments
      • Table Novo Nordisk - Geographic focus
      • Table Novo Nordisk - Segment focus
      • Table Novo Nordisk - Key offerings
    • Vivus
      • Table Vivus - Overview
      • Table Vivus - Business segments
      • Table Vivus - Organizational developments
      • Table Vivus - Geographic focus
      • Table Vivus - Key offerings
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report